In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
NCT ID: NCT02916394
Last Updated: 2020-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2018-09-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Displacement Distance and Stabilization Time for Liver Fiducial Marker
NCT05816837
Tumor Response in Hypofractionated Radiotherapy
NCT02854449
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
NCT02113423
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
NCT01934478
Radiotherapy Safety for Liver Malignancies Using Post-Treatment Imaging
NCT07346573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++
Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
68Ga-NODAGA-ZIGF-1R:4：40
No Intervention
68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++
Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
68Ga-NODAGA-ZIGF-1R:4：40
No Intervention
68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+
Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
68Ga-NODAGA-ZIGF-1R:4：40
No Intervention
68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers
Patients in this group who are healthy volunteer.
68Ga-NODAGA-ZIGF-1R:4：40
No Intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-NODAGA-ZIGF-1R:4：40
No Intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. More than 18 years old
3. A life expectancy of at least 12 weeks
4. Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
5. Written informed consent
Exclusion Criteria
2. Pregnancy
3. do not want to write informed consent。
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Harbin Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yingying Sun
Chief
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baozhong Shen
Role: STUDY_CHAIR
The Fourth Hospital of Harbin Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.